查詢結果分析
相關文獻
- High-Dose Cytarabine and Mitoxantrone as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma
- 抗癌新藥Rituximab--以抗CD20單株抗體來治療復發性低惡性度非何杰金氏淋巴瘤
- 非何杰金氏淋巴瘤染色體的變化
- 非何杰金氏淋巴瘤的分子生物學變化
- Primary Pleural Low Grade Lymphoma--A Case Report
- Mucosa-Associated Lymphoid Tissue Lymphoma of Salivary Gland--2 Case Reports
- Testicular Non-Hodgkin's Lymphoma: A Case Report
- Autologous Peripheral Blood Stem Cell Transplantation for Patients with Malignancies: The Tri-Service General Hospital Experience
- 非何杰金氏淋巴瘤併雙側腎上腺侵犯引起之腎上腺功能低下--一病例報告
- 非何杰金氏淋巴瘤的新分類法
頁籤選單縮合
題 名 | High-Dose Cytarabine and Mitoxantrone as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma=合併使用高劑量Cytarabine及Mitoxantrone作為復發性淋巴瘤之治療 |
---|---|
作 者 | 王緯書; 曾成槐; 邱宗傑; 劉俊煌; 樊聖; 陳博明; | 書刊名 | 中華醫學雜誌 |
卷 期 | 57:2 1996.02[民85.02] |
頁 次 | 頁100-105 |
分類號 | 415.6 |
關鍵詞 | 高劑量ara-C; 骨髓抑制; 非何杰金氏淋巴瘤; High-dose ara-C; Mitoxantrone; Myelosuppression; Non-Hodgkin's lymphoma; |
語 文 | 英文(English) |
中文摘要 | 背景 文獻指出,單獨使用高劑量cytarabine(ara-C)或合併高劑量ara-C 及mitoxantrone均可用來治療復發性非何杰金氏淋巴瘤。在本研究中,我們合併 使用高劑量ara-C及mitoxantrone來治療14例復發性非何杰金氏淋巴瘤的病患, 並探討其療效及毒性。 方法 ara-C每次每平方公尺體表面積靜注給予3公克,靜注時間為2小時,每 12小時給藥七次,連續4天(第l天至第4天),共8劑。mitoxantrone每天每平 方公尺體表面積靜注給予6公絲,連續5天(第1天至第5天)。臨床療效以及藥 物毒性之評估依照世界衛生組織之標準(WHO Criteria)。 結果 4例(28%)達到完全緩解,平均緩解期為2.9個月。2例部份緩解,5例於 治療後1個月內死亡。骨髓抑制合併續發性的感染為最主要的併發症。化療後 產生嚴重白血球缺乏(<1,000/uL)的平均天數為20天,產生嚴重血小板缺乏 (<50.000/uL)則為24天。骨髓以外的毒性包括l00%的病例出現脫髮,93%口腔黏 膜發炎,43%肝毒性,36%皮膚病變,28%中樞神經毒性,以及7%結膜炎 結論 對於復發性非何杰金氏淋巴瘤,仍有一部份病例可藉合併使用高劑量 ara-C以及mitoxantrone而達到完全緩解,惟此療法最主要的副作用為嚴重的骨 髓抑制。 |
英文摘要 | Background. High-dose cytarabine (ara-C) alone or in combination with mitoxantrone each has shown to be active in therapeutic trials of refractory non- Hodgkin's lymphoma (NHL). In this study, we administered these two drugs to 14 patients with advanced and refractory NHL. Methods. Ara-C was administered at a dosage of 3 gm/sqm for 2-hour intravenous infusion every 12 hours from day 1 to day 4 (8 doses), and mitoxantrone was given at a dosage of 6 mg/sqm/day for 1-hour intravenous infusion from day 1 to day 5. The clinical efficacy and toxicity were assessed by WHO criteria. Results. Four patients (28%) attained complete remission (CR) and 2 had partial remission (PR). Of the 4 CR patients, the remission lasted 5 months in one patient and 4 months in another. The remaining 2 patients had CR of only 1.3 months. Myelosuppression with subsequent infection was the major toxicity of this regimen. Severe neutropenia ( < 1,000/uL) lasted for an average of 20 days, and thrombocytopenia ( < 50,000/ uL) 24 days. Nonmyeloid toxicities included 100% alopecia, 93% stomatitis, 43% hepatotoxicity, 36% dermatitis, 28% CNS toxicity and 7% chemical conjunctivitis. Conclusions. A proportion of refrcatory NHL patients will respond to high-dose ara-C + mitoxantrone, despite that severe myelosuppression is frequently encountered. |
本系統中英文摘要資訊取自各篇刊載內容。